# A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

> **NCT01105598** · PHASE1 · COMPLETED · sponsor: **Esperion Therapeutics, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Mild Dyslipidemia

## Interventions

- **DRUG:** ETC-1002 or placebo
- **DRUG:** ETC-1002 or placebo
- **DRUG:** ETC-1002 or placebo

## Key facts

- **NCT ID:** NCT01105598
- **Lead sponsor:** Esperion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-20
- **Primary completion:** 2010-10-02
- **Final completion:** 2010-10-02
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01105598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01105598, "A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01105598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*